<DOC>
	<DOCNO>NCT01082341</DOCNO>
	<brief_summary>It possible safely protect human volunteer immunize P. vivax irradiate sporozoite P. vivax challenge live sporozoite .</brief_summary>
	<brief_title>Immunization Human Volunteers With P. Vivax Irradiated Sporozoites</brief_title>
	<detailed_description>Title : Phase 1 Phase 2a Clinical Trial : Immunization human volunteer P. vivax irr-spz . ( Short name : Irrad-SPZ ) Population 27 healthy adult volunteer , male non-pregnant female , 18-45 year age , fulfill inclusion/exclusion criterion ( describe ) determine clinical history serological test . Approximately 20 parasitized blood-donor volunteer require infected Anopheles mosquito use immunize volunteer total 1000-1500 infect mosquito , 8-10 month . Afterwards challenge prove protection . Number Sites : 2 Study Duration : 2 year . Subject Duration : Step1 : 1-2 hour blood donor ; Step 2 3 : 2 year immunized volunteer Objectives Primary • To assess safety protective efficacy P. vivax irradiate sporozoite vaccination . Secondary - To determine immune response duration elicit P. vivax challenge human Fy ( + ) volunteer previously immunize irr-spz , compare non-immunized human volunteer . - To determine immune response duration elicit irr-spz immunization scheme human Fy ( + ) volunteer ; compare immunization scheme non irr-spz Fy ( - ) participant , also control exposed mosquito bite scheme immunization use mosquito without parasite infection . - To study new antigen potentially useful induce pre-erythrocytic protection P. vivax malaria infection</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>• Healthy 18 45 year old man nonpregnant woman . To capacity sign inform consent free voluntary way . Have acceptable understanding clinical trial approval questionnaire regard information give consent process . Obligatory use adequate contraconceptive method begin recruitment screening time three month last immunization Do chronic acute disease . These condition determine clinical history , physical exam laboratory test . To accept travel malaria endemic area clinical trial To telephone home mobile phone permit permanent contact follow He ( ) manifest willing participated step clinical trial . Volunteers le 18 old year 45 old year . Pregnant suckle woman exclude . Pregnancy determine interview , serum Bsubunit chorionic gonadotrophin test . History moderate severe insect , food allergy . G6PD deficiency Hb genetic defect ( example ; sickle cell disease ) Previous malaria infection demonstrate think smear , PCR specific antimalarial antibody . If subject previously participate malarial vaccine trial . Clinical record allergies drug insect bite . Symptoms , sign data laboratory test suggest physician systemic disorder like renal , hepatic , cardiovascular , pulmonary , psychiatric disorder illness could interfere result clinical trial could compromise health volunteer . To antibody hepatitis C , VIH , hepatitis B superficial antigen and/or hepatitis B core antibody . To abnormality parameter assess blood laboratory test . Baseline value establish initiation clinical trial . Presence history autoimmune disease ; Asthma , lupus , rheumatoid arthritis , Graves 's disease , Hashimoto tyroiditis , others . History surgical removal spleen ( splenectomy ) . Volunteer medical treatment know alter immune system 3 month recruitment , ; corticosteroid , chemotherapeutic agent , fludarabine , cyclosporine , tacrolimus , mycophenolate mofetil , rapamycine , ATG , alemtuzumab . Alcoholism drug abuse may interfere social relationship individual .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>GCP Good Clinical Practice</keyword>
	<keyword>IFAT Indirect Immunofluorescence antibody test</keyword>
	<keyword>MFA Membrane Feeding Assay</keyword>
	<keyword>N Number ( typically refer subject )</keyword>
	<keyword>RBC Red Blood Cells</keyword>
	<keyword>SOP Standard Operating Procedure</keyword>
	<keyword>TBS Thick blood smear</keyword>
	<keyword>P. Vivax</keyword>
	<keyword>irradiate sporozoite vaccination .</keyword>
</DOC>